Practical Guidance on the Use of Cladribine Tablets in the Management or Relapsing Multiple Sclerosis: Expert Opinion from Qatar

References

• Freeman L, Longbrake EE, Coyle PK, Hendin B, Vollmer T. High-efficacy therapies for treatment-naïve individuals with relapsing-remitting multiple sclerosis. CNS Drugs. 2022;36(12):1285–1299. doi:10.1007/s40263-022-00965-7
   PubMed Web of Science ®Google Scholar
• AlSharoqi IA, Aljumah M, Bohlega S, et al. Immune reconstitution therapy or continuous immunosuppression for the management of active relapsing-remitting multiple sclerosis patients? A narrative review. Neurol Ther. 2020;9(1):55–66. doi:10.1007/s40120-020-00187-3
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Sellebjerg F. Pulsed immune reconstitution therapy in multiple sclerosis. Ther Adv Neurol Disord. 2019;12:1756286419836913. doi:10.1177/1756286419836913
   Web of Science ®Google Scholar
• Giovannoni G. Personalized medicine in multiple sclerosis. Neurodegener Dis Manag. 2017;7(6s):13–17. doi:10.2217/nmt-2017-0035
   PubMedGoogle Scholar
• Yamout B, Sahraian M, Bohlega S, et al. Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines. Mult Scler Relat Disord. 2020;37:101459. doi:10.1016/j.msard.2019.101459
   PubMed Web of Science ®Google Scholar
• Caffrey M Bringing real-world data to multiple sclerosis treatment decisions. Conference report. Am J Manag Care September; 2019. Available from: https://www.ajmc.com/view/bringing-realworld-data-to-multiple-sclerosis-treatment-decisions. Accessed July, 2023.
   Google Scholar
• Fox RJ, Mehta R, Pham T, Park J, Wilson K, Bonafede M. Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis. BMC Neurol. 2022;22(1):211. doi:10.1186/s12883-022-02738-7
   PubMed Web of Science ®Google Scholar
• Deleu D, Canibaño B, Mesraoua B, et al. Management of relapsing-remitting multiple sclerosis in Qatar: an expert consensus. Curr Med Res Opin. 2020;36(2):251–260. doi:10.1080/03007995.2019.1669378
   PubMed Web of Science ®Google Scholar
• Ibrahim F, Canibano B, Deleu D. Increasing prevalence of multiple sclerosis in Qatar: 27-year data. Mult Scler J. 2020;26(S3):1.
   Google Scholar
• Kishner S, Weilenman ZN. Kurtzke expanded disability status scale. Medscape drugs and diseases; 2023. Available from: https://emedicine.medscape.com/article/2172461. Accessed July, 2023.
   Google Scholar
• Garcia-Cañibano B, Zamrath Zahir F, Safan A, Ibrahim F, Deleu D. Two years efficacy and safety results from real world experience for cladribine tablets in management of relapsing multiple sclerosis in Qatar. Mult Scler J. 2022;28(Issue 3_Suppl):391.
   Web of Science ®Google Scholar
• Clavelou P, Giovanni Castelnovo G, Valérie Pourcher V, et al. Expert narrative review of the safety of cladribine tablets for the management of relapsing multiple sclerosis. Neurol Ther. 2023;12(5):1457–1476. doi:10.1007/s40120-023-00496-3)
   PubMed Web of Science ®Google Scholar
• Nabizadeh F, Mohamadi M, Rahmani S, et al. Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis. Neurol Sci. 2023;2023:1–13.
   Google Scholar
• Leist T, Cook S, Comi G, et al. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Mult Scler Relat Disord. 2020;46:102572. doi:10.1016/j.msard.2020.102572
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416–426. doi:10.1056/NEJMoa0902533
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Soelberg Sorensen P, Cook S, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler. 2018;24(12):1594–1604. doi:10.1177/1352458517727603
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Mavenclad, INN-cladribine. Available from: https://www.ema.europa.eu/en/documents/product-information/mavenclad-epar-product-information_en.pdf. Accessed July, 2023.
   Google Scholar
• Signori A, Saccà F, Lanzillo R, et al. Cladribine vs other drugs in MS: merging randomized trial with real-life data. Neurol Neuroimmunol Neuroinflamm. 2020;7(6):e878. doi:10.1212/NXI.0000000000000878
   PubMed Web of Science ®Google Scholar
• Bartosik-Psujek H, Kaczyński Ł, Górecka M, et al. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis. Mult Scler Relat Disord. 2021;49:102769. doi:10.1016/j.msard.2021.102769
   PubMed Web of Science ®Google Scholar
• Siddiqui MK, Khurana IS, Budhia S, Hettle R, Harty G, Wong SL. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis. Curr Med Res Opin. 2018;34(8):1361–1371. doi:10.1080/03007995.2017.1407303
   PubMed Web of Science ®Google Scholar
• Piasecka-Stryczyńska K, Kaczyński Ł, Rolka M, et al. Systematic review and network meta-analysis (NMA) for cladribine tablets in achieving sustained disability improvement (SDI) in multiple sclerosis. Neurol Neurochir Pol. 2022;56(6):480–489. doi:10.5603/PJNNS.a2022.0068
   PubMed Web of Science ®Google Scholar
• Śladowska K, Kawalec P, Holko P, Osiecka O. Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. Neurol Sci. 2022;43(9):5479–5500. doi:10.1007/s10072-022-06197-3
   PubMedGoogle Scholar
• Giovannoni G, Soelberg Sorensen P, Cook S, et al. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: a post hoc analysis of the CLARITY study. Mult Scler. 2019;25(6):819–827. doi:10.1177/1352458518771875
   PubMed Web of Science ®Google Scholar
• Scalfari A, Romualdi C, Nicholas RS, et al. The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis. Neurology. 2018;90(24):e2107–e2118. doi:10.1212/WNL.0000000000005685
   PubMed Web of Science ®Google Scholar
• Engel S, Zipp F. Preventing disease progression in multiple sclerosis-insights from large real-world cohorts. Genome Med. 2022;14(1):41. doi:10.1186/s13073-022-01044-8
   PubMed Web of Science ®Google Scholar
• Fambiatos A, Jokubaitis V, Horakova D, et al. Risk of secondary progressive multiple sclerosis: a longitudinal study. Mult Scler. 2020;26(1):79–90. doi:10.1177/1352458519868990
   PubMed Web of Science ®Google Scholar
• Espiritu A, Oh J Prognostic factors in multiple sclerosis. Prediction of highly active disease and rapid disability accumulation is crucial to optimizing clinical outcomes over time. Practical Neurol 2022;February:44–48. Available from: https://practicalneurology.com/articles/2022-feb/prognostic-factors-in-multiple-sclerosis. Accessed July, 2023.
   Google Scholar
• Lebrun-Frénay C, Rollot F, Mondot L, et al. Risk factors and time to clinical symptoms of multiple sclerosis among patients with radiologically isolated syndrome. JAMA Netw Open. 2021; 4:e2128271.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Mavenclad - Accessdata.fda.gov. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022561s000lbl.pdf. Accessed July, 2023.
   Google Scholar
• Alroughani R, Inshasi J, Al-Asmi A, et al. Expert consensus from the Arabian Gulf on selecting disease-modifying treatment for people with multiple sclerosis according to disease activity. Postgrad Med. 2020;132(4):368–376. doi:10.1080/00325481.2020.1734394
   PubMed Web of Science ®Google Scholar
• Filippi M, Amato MP, Centonze D, et al. Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol. 2022;269(10):5382–5394. doi:10.1007/s00415-022-11193-w
   PubMed Web of Science ®Google Scholar
• Casanova B, Quintanilla-Bordás C, Gascón F. Escalation vs. Early intense therapy in multiple sclerosis. J Pers Med. 2022;12(1):119. doi:10.3390/jpm12010119
   PubMed Web of Science ®Google Scholar
• Stankiewicz JM, Weiner HL. An argument for broad use of high efficacy treatments in early multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2019;7(1):e636. doi:10.1212/NXI.0000000000000636
   PubMed Web of Science ®Google Scholar
• Prosperini L, Mancinelli CR, Solaro CM, et al. Induction versus escalation in multiple sclerosis: a 10-year real world study. Neurotherapeutics. 2020;17(3):994–1004. doi:10.1007/s13311-020-00847-0
   PubMed Web of Science ®Google Scholar
• Iaffaldano P, Lucisano G, Caputo F, et al. Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Ther Adv Neurol Disord. 2021;14:17562864211019574. doi:10.1177/17562864211019574
   Web of Science ®Google Scholar
• Spelman T, Magyari M, Piehl F, et al. Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies. JAMA Neurol. 2021;78(10):1197–1204. doi:10.1001/jamaneurol.2021.2738
   PubMed Web of Science ®Google Scholar
• Wilson LS, Loucks A, Gipson G, et al. Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis. Int J MS Care. 2015;17(2):74–82. doi:10.7224/1537-2073.2013-053
   PubMedGoogle Scholar
• Garcia-Dominguez JM, Muñoz D, Comellas M, Gonzalbo I, Lizán L, Polanco Sánchez C. Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment. Patient Prefer Adherence. 2016;10:1945–1956. doi:10.2147/PPA.S114619
   PubMed Web of Science ®Google Scholar
• Berardi A, Siddiqui MK, Treharne C, Harty G, Wong SL. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches. Curr Med Res Opin. 2019;35(8):1371–1378. doi:10.1080/03007995.2019.1585779
   PubMed Web of Science ®Google Scholar
• Habek M, Drulovic J, Brecl Jakob G, et al. Treatment with cladribine tablets beyond year 4: a position statement by southeast European multiple sclerosis centers. Neurol Ther. 2023;12(1):25–37. doi:10.1007/s40120-022-00422-z
   PubMed Web of Science ®Google Scholar
• Sørensen PS, Centonze D, Giovannoni G, et al. Expert opinion on the use of cladribine tablets in clinical practice. Ther Adv Neurol Disord. 2020;13:1756286420935019. doi:10.1177/1756286420935019
   Web of Science ®Google Scholar
• Meuth SG, Bayas A, Kallmann B, et al. Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4. Expert Opin Pharmacother. 2022;23(13):1503–1510. doi:10.1080/14656566.2022.2106783
   PubMed Web of Science ®Google Scholar
• Bose G, Rush C, Atkins HL, Freedman MS. A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis. Mult Scler Relat Disord. 2021;52:102945. doi:10.1016/j.msard.2021.102945
   PubMed Web of Science ®Google Scholar
• Rauma I, Viitala M, Kuusisto H, et al. Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study. Mult Scler Relat Disord. 2022;61:103755. doi:10.1016/j.msard.2022.103755
   PubMed Web of Science ®Google Scholar
• Patti F, Visconti A, Capacchione A, Roy S, Trojano M, Study Group CLARINET-MS. Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS). Ther Adv Neurol Disord. 2020;13:1756286420922685. doi:10.1177/1756286420922685
   Web of Science ®Google Scholar
• Frau J, Coghe G, Lorefice L, Fenu G, Musu L, Cocco E. Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis. J Neurol. 2019;266(6):1405–1411. doi:10.1007/s00415-019-09272-6
   PubMed Web of Science ®Google Scholar
• Coles AJ, Arnold DL, Bass AD, et al. Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. Ther Adv Neurol Disord. 2021;14:1756286420982134. doi:10.1177/1756286420982134
   Google Scholar
• Steingo B, Al Malik Y, Bass AD, et al. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. J Neurol. 2020;267(11):3343–3353. doi:10.1007/s00415-020-09983-1
   PubMed Web of Science ®Google Scholar
• Russo CV, Saccà F, Frau J, et al. A real-world study of alemtuzumab in a cohort of Italian patients. Eur J Neurol. 2022;29(1):257–266. doi:10.1111/ene.15121
   PubMed Web of Science ®Google Scholar
• Alroughani R, Inshasi J, Al-Asmi A, et al. Disease-modifying drugs and family planning in people with multiple sclerosis: a consensus narrative review from the gulf region. Neurol Ther. 2020;9(12):265–280. doi:10.1007/s40120-020-00201-8
   PubMedGoogle Scholar
• De Sèze J, Suchet L, Mekies C, et al. The place of immune reconstitution therapy in the management of relapsing multiple sclerosis in France: an Expert Consensus. Neurol Ther. 2023;12(2):351–369. doi:10.1007/s40120-022-00430-z
   PubMed Web of Science ®Google Scholar
• Dobson R, Dassan P, Roberts M, et al. UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines. Pract Neurol. 2019;19(2):106–114. doi:10.1136/practneurol-2018-002060
   PubMedGoogle Scholar
• Mardan J, Hussain MA, Allan M, Grech LB. Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression. J Manag Care Spec Pharm. 2021;27(9):1273–1295. doi:10.18553/jmcp.2021.27.9.1273
   PubMed Web of Science ®Google Scholar